LONDON / MUMBAI — April 24, 2026 : UK-based advanced air mobility developer LYTE Aviation Ltd has received ten conditional purchase orders from Vman Aviation Services IFSC Pvt Ltd for its SkyClinic vertical take-off and landing (VTOL) aircraft, in a deal valued at €500 million. The agreement includes milestone-linked deposits totaling €10 million and represents a significant early-stage commitment in the emerging aeromedical mobility sector.
Agreement Structure and Strategic Rationale
The order was placed by Vman Aviation Services, a boutique aviation leasing firm established in India’s GIFT City financial hub. The company intends to deploy the aircraft to address gaps in healthcare infrastructure, particularly across Tier 2 and Tier 3 cities, remote regions, and disaster-affected areas.
Vishok Mansingh, Chief Executive Officer of Vman Aviation Services, stated that the SkyClinic platform is designed to deliver advanced medical capabilities directly to underserved areas where building and maintaining conventional hospital infrastructure is not feasible. The initiative is aligned with broader efforts to improve healthcare accessibility and reduce the need for patient transfers to major urban centres.
Aircraft Design and Technical Specifications
The SkyClinic is a purpose-built aeromedical aircraft derived from LYTE Aviation’s LA-44 SkyBus platform. It uses a tandem tilt-wing configuration and hybrid-hydrogen electric propulsion system.
Key technical characteristics include a payload capacity of 4.5 tonnes and an operational range of up to 1,000 kilometres. The aircraft is designed to operate with minimal infrastructure, requiring approximately 50 metres of landing space and no dependence on traditional runways or helipads.
The propulsion system is based on LYTE Aviation’s proprietary “PowerBridge” architecture, integrating combustion engines, electric motors, liquid hydrogen fuel cells, and compatibility with sustainable aviation fuels. Following a preliminary design review completed in 2025, the aircraft’s configuration was revised from eight engines to four, improving efficiency, reliability, and maintenance requirements.
Medical Capabilities and Onboard Systems
Unlike conventional air ambulances, the SkyClinic is configured as a deployable flying hospital. The cabin includes a fully equipped surgical suite capable of accommodating up to six patients simultaneously.
The onboard medical infrastructure features an operating theatre designed to support remote robotic surgery, advanced diagnostic equipment, and continuous patient monitoring systems. The aircraft is also equipped with high-speed 5G and 6G connectivity, enabling real-time data transmission and remote specialist consultation.
These capabilities are intended to support a wide range of use cases, including emergency response, specialised medical outreach, and humanitarian assistance in underserved or inaccessible locations.
Operational Use Cases and Broader Applications
In addition to civilian healthcare delivery, the SkyClinic platform is designed for deployment in disaster relief scenarios and conflict zones. Its rapid deployment capability and integrated medical logistics systems allow it to function as a mobile field hospital.
The aircraft’s potential applications extend to military use cases, including frontline medical response, casualty evacuation, and support for operations in remote or infrastructure-limited environments.
Programme Status and Development Timeline
LYTE Aviation, founded in 2023 and headquartered in London, is developing a portfolio of heavyweight hybrid-hydrogen-electric VTOL aircraft. This includes the passenger-focused SkyBus, the cargo-oriented SkyTruck, and the medical SkyClinic variant.
The company completed a preliminary design review in 2025 and is progressing toward the development of a subscale prototype. Discussions with fuel cell and propulsion system partners are ongoing as part of the next phase of development.
The SkyClinic orders contribute to LYTE Aviation’s total pre-order pipeline, which the company states is valued at approximately €1.42 billion across its aircraft portfolio.
Commercial Outlook and Next Steps
Freshta Farzam, Chief Executive Officer of LYTE Aviation, described the agreement as an indication of market interest in advanced aeromedical mobility solutions and validation of the company’s platform strategy.
The current agreement remains conditional, with conversion to firm orders dependent on specified technical and commercial milestones. Neither LYTE Aviation nor Vman Aviation Services disclosed timelines for certification, delivery schedules, or entry-into-service dates.
Both companies indicated that further updates regarding programme progress and contractual developments will be provided as milestones are met.
——— End of Article ———
